ADC Therapeutics SA
NYSE:ADCT
EV/IC
Enterprise Value to IC
Enterprise Value to Invested Capital (EV/IC) ratio is a valuation multiple that measures the dollars in Enterprise Value for each dollar of capital invested by shareholders and lenders.
Market Cap | EV/IC | ||||
---|---|---|---|---|---|
CH |
ADC Therapeutics SA
NYSE:ADCT
|
409.3m USD | 9.2 | ||
US |
Abbvie Inc
NYSE:ABBV
|
290.1B USD | 3.6 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
141.4B USD | 2.9 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
101.3B USD | 12.3 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
98.6B USD | 17.9 | ||
AU |
CSL Ltd
ASX:CSL
|
131.7B AUD | 2.8 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
83.4B USD | 1.9 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 19.3 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
39.5B USD | 3.4 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
27.8B USD | 1.3 | ||
IE |
Horizon Therapeutics PLC
NASDAQ:HZNP
|
26.6B USD | 4 |
EV/IC Forward Multiples
Forward EV/IC multiple is a version of the EV/IC ratio that uses forecasted invested capital for the EV/IC calculation. 1-Year, 2-Years, and 3-Years forwards use invested capital forecasts for 1, 2, and 3 years ahead, respectively.